Portfolio Update

BLACKROCK SMALLER COMPANIES TRUST plc All information is at 31 May 2008 and unaudited. Performance at month end is calculated on a capital only basis One Three One Three Five Month Months Year Years Years Net asset value 6.0% 8.0% -9.6% 67.6% 162.9% Share price 9.4% 8.1% -11.6% 76.0% 187.7% HGSC ex Inv Trust + AIM* 1.1% -1.5% -21.5% 14.3% 55.8% Sources: BlackRock and Datastream *With effect from 1 September 2007 the Hoare Govett Smaller Companies plus AIM (ex Investment Companies) Index replaced the FTSE SmallCap Index (ex Investment Companies) as the Company's benchmark. For the one year, three year and five year periods above the index has been blended to reflect this. At month end Net asset value (debt at par value): 440.49p Net asset value (debt at fair value): 437.19p Net asset value incl. Income (debt at par value) 442.95p* Net asset value incl. Income (debt at fair value) 439.65p* Share price: 367.50p Discount to Capital only NAV (debt at par value): 16.6% Discount to Capital only NAV (debt at fair value): 15.9% Net yield: 1.3% Total assets: £230.0m^ Gearing: 6.4% Ordinary shares in issue^: 48,509,708 (* includes net revenue of 2.46p) (^ includes current year revenue) Ten Largest Sector Weightings % of Total Assets Support Services 14.0 Software & Computer Services 11.9 Industrial Metals & Mining 9.6 Oil & Gas Producers 9.0 Industrial Engineering 8.7 Financial Services 7.9 Aerospace & Defence 6.3 Electronic & Electrical Equipment 4.6 Media 3.7 Health Care Equipment & Services 3.6 Total 79.3 Ten Largest Equity Investments (in alphabetical order) Company Albidon Aveva Group Chloride Group Connaught Dechra Pharmaceuticals Hill & Smith Holdings ITE Group Rathbone Brothers Spirax-Sarco Engineering Victrex Commenting on the markets, Mike Prentis, representing the Investment Manager noted: During May the Company's NAV rose by 6.0%. The benchmark index rose by 1.1%, whilst the FTSE100 index fell by 0.5%. In relative terms, the best stock contributions came from Dechra Pharmaceuticals, Chloride Group, ITE Group, Albidon, Aveva Group and Nighthawk Energy. Dechra shares are very defensive, given that health-related spending on dogs, cats and other pets is generally regarded as non-discretionary. FDA approval for Vetoryl should come through this year. Chloride shares were firm on hopes of a competitive bid situation developing. In early June bid talks were terminated; underlying trading remains strong. ITE produced strong year end results; a significant part of its revenues are Euro denominated, and this is leading to earnings upgrades. Albidon continues to move towards production from its Munali nickel mine. Aveva again produced strong results; management remain very confident about prospects. Nighthawk announced further positive drilling success. The worst performer during the month was Detica, although this cost us only 13 basis points in relative terms. In fact Detica has just produced good full year results and management remain confident; the shares gave up some ground after a good run. New holdings included our first investment in an IPO for some time, OPG Power Ventures. OPG owns power stations in India and was raising money to build several new plants. We added to our holding in Hampson Industries helping to fund a major acquisition. We sold several of our holdings in oil & gas producers, including holdings in Dana Petroleum, JKX Oil & Gas and Oilexco. These have all performed well in recent months. We also sold our long standing holding in Chaucer Holdings, taking a view that Lloyd's underwriters may remain dull for some time. Latest information is available by typing www.blackrock.co.uk/its on the internet, "BLRKINDEX" on Reuters, "BLRK" on Bloomberg or "8800" on Topic 3 (ICV terminal). 26 June 2008
UK 100

Latest directors dealings